{"title":"CORR Insights®:不可逆电穿孔对兔骨髓炎金黄色葡萄球菌模型有何影响?","authors":"J. Jennings","doi":"10.1097/CORR.0000000000000938","DOIUrl":null,"url":null,"abstract":"Osteomyelitis is a rare, but serious bone infection that may result from trauma, hematogenous spread, or chronic open wounds [12]. Treating osteomyelitis can be challenging because of antimicrobial resistance [9], biofilm formation [19], the presence of an avascular necrotic sequestrum [3], or internalization of bacteria within osteoblasts [25]. For elective surgical procedures like joint arthroplasty, antimicrobial therapy and aseptic techniques successfully prevent infection approximately 99% of the time [22], but once osteomyelitis has been established, the likelihood of treatment success varies widely, from 25% to 90% for established osteomyelitis, depending on many factors [6]. Early in the infectious process, antibiotic chemotherapy alone may eradicate osteomyelitis [5], though in moreadvanced or more severe infections, surgical débridement often comes into the picture [3], and surgical approaches may be augmented with targeted delivery of antibiotics directly to the affected tissue through local delivery devices such as antibiotic-loaded bone cement, calcium sulfate, or polymer sponges and gels [7, 10, 16, 24]. However, infection recurrence resulting from inadequate débridement or not clearing dormant biofilm bacteria can result in infection persistence, the need for repeat (andmore-aggressive) débridement, and even amputation of the affected limb [4, 8]. Novel therapeutics that both treat affected tissue and eradicate bacteria are desperately needed. The aim of the exploratory study by Muñoz and colleagues [13] is to determine whether a novel technique currently investigated for ablation of cancerous soft-tissue tumors might also have effective application in the treatment of osteomyelitis. The small preclinical study only followed animal outcomes for a 28-day period following treatment, but nonetheless provides promising evidence of a synergistic effect in killing Staphylococcus aureus within osteomyelitic bone.","PeriodicalId":10465,"journal":{"name":"Clinical Orthopaedics & Related Research","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CORR Insights®: What Are the Effects of Irreversible Electroporation on a Staphylococcus aureus Rabbit Model of Osteomyelitis?\",\"authors\":\"J. Jennings\",\"doi\":\"10.1097/CORR.0000000000000938\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Osteomyelitis is a rare, but serious bone infection that may result from trauma, hematogenous spread, or chronic open wounds [12]. Treating osteomyelitis can be challenging because of antimicrobial resistance [9], biofilm formation [19], the presence of an avascular necrotic sequestrum [3], or internalization of bacteria within osteoblasts [25]. For elective surgical procedures like joint arthroplasty, antimicrobial therapy and aseptic techniques successfully prevent infection approximately 99% of the time [22], but once osteomyelitis has been established, the likelihood of treatment success varies widely, from 25% to 90% for established osteomyelitis, depending on many factors [6]. Early in the infectious process, antibiotic chemotherapy alone may eradicate osteomyelitis [5], though in moreadvanced or more severe infections, surgical débridement often comes into the picture [3], and surgical approaches may be augmented with targeted delivery of antibiotics directly to the affected tissue through local delivery devices such as antibiotic-loaded bone cement, calcium sulfate, or polymer sponges and gels [7, 10, 16, 24]. However, infection recurrence resulting from inadequate débridement or not clearing dormant biofilm bacteria can result in infection persistence, the need for repeat (andmore-aggressive) débridement, and even amputation of the affected limb [4, 8]. Novel therapeutics that both treat affected tissue and eradicate bacteria are desperately needed. The aim of the exploratory study by Muñoz and colleagues [13] is to determine whether a novel technique currently investigated for ablation of cancerous soft-tissue tumors might also have effective application in the treatment of osteomyelitis. The small preclinical study only followed animal outcomes for a 28-day period following treatment, but nonetheless provides promising evidence of a synergistic effect in killing Staphylococcus aureus within osteomyelitic bone.\",\"PeriodicalId\":10465,\"journal\":{\"name\":\"Clinical Orthopaedics & Related Research\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Orthopaedics & Related Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/CORR.0000000000000938\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Orthopaedics & Related Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CORR.0000000000000938","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CORR Insights®: What Are the Effects of Irreversible Electroporation on a Staphylococcus aureus Rabbit Model of Osteomyelitis?
Osteomyelitis is a rare, but serious bone infection that may result from trauma, hematogenous spread, or chronic open wounds [12]. Treating osteomyelitis can be challenging because of antimicrobial resistance [9], biofilm formation [19], the presence of an avascular necrotic sequestrum [3], or internalization of bacteria within osteoblasts [25]. For elective surgical procedures like joint arthroplasty, antimicrobial therapy and aseptic techniques successfully prevent infection approximately 99% of the time [22], but once osteomyelitis has been established, the likelihood of treatment success varies widely, from 25% to 90% for established osteomyelitis, depending on many factors [6]. Early in the infectious process, antibiotic chemotherapy alone may eradicate osteomyelitis [5], though in moreadvanced or more severe infections, surgical débridement often comes into the picture [3], and surgical approaches may be augmented with targeted delivery of antibiotics directly to the affected tissue through local delivery devices such as antibiotic-loaded bone cement, calcium sulfate, or polymer sponges and gels [7, 10, 16, 24]. However, infection recurrence resulting from inadequate débridement or not clearing dormant biofilm bacteria can result in infection persistence, the need for repeat (andmore-aggressive) débridement, and even amputation of the affected limb [4, 8]. Novel therapeutics that both treat affected tissue and eradicate bacteria are desperately needed. The aim of the exploratory study by Muñoz and colleagues [13] is to determine whether a novel technique currently investigated for ablation of cancerous soft-tissue tumors might also have effective application in the treatment of osteomyelitis. The small preclinical study only followed animal outcomes for a 28-day period following treatment, but nonetheless provides promising evidence of a synergistic effect in killing Staphylococcus aureus within osteomyelitic bone.